Abstracts tagged "gout"

Abstract Number: 1793 • ACR Convergence 2022
Prevalence of HLA B*5801 Allele Among African American Patients with Gout in an Academic Health Center
Namitha Nair, Dipanjan Debnath and FLORINA CONSTANTINESCU, MedStar Washington Hospital Center, Washington, DC
Background/Purpose: The presence of the HLA-B*5801 allele is strongly associated with Allopurinol Hypersensitivity Syndrome (AHS) manifesting as severe cutaneous adverse reactions (SCARs) like Drug rash…
Abstract Number: 1811 • ACR Convergence 2022
Urate Lowering Therapy Initiation in Hospitalized Patients with Acute Gout Flares
Emily Fan¹ and Megan Krause², ¹University of Kansas School of Medicine, Kansas City, KS, ²University of Kansas, Kansas City, KS
Background/Purpose: Identifying patients with gout who would benefit from urate lowering therapies (ULT) is of utmost importance to help limit both pain and functional pain.…
Abstract Number: 2203 • ACR Convergence 2022
Changes in Tophus Composition During Urate-Lowering Therapy: A Dual Energy CT Study
Leanne Chen¹, Gregory Gamble¹, Anne Horne¹, Jill Drake², Anthony Doyle¹, Till Uhlig³, Lisa Stamp² and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, New Zealand, ³Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: The gouty tophus is an organized structure composed of monosodium urate (MSU) crystals and chronic inflammatory soft tissue. Long-term urate-lowering therapy leads to gradual…
Abstract Number: 1239 • ACR Convergence 2022
The Utility of Dual-Energy Computed Tomography in the Diagnosis of Gout
Priya Parikh¹, Kim Nguyen², Priyanka Vashisht², Casey Reed³ and Jon Jacobson³, ¹University of Cincinnati Medical Center, Department of Internal Medicine, Cincinnati, OH, ²University of Cincinnati Medical Center, Department of Rheumatology, Cincinnati, OH, ³University of Cincinnati Medical Center, Department of Radiology, Cincinnati, OH
Background/Purpose: The diagnostic gold standard of the diagnosis of gout is joint aspiration and the identification of monosodium urate (MSU) crystals under polarized light microscopy.…
Abstract Number: 1794 • ACR Convergence 2022
Characteristics of Patients with Repeat Visits for Acute Gout at a University Hospital Emergency Department
David Lim¹, Manushi Aggarwal¹ and Marven Cabling², ¹Loma Linda University Health, Redlands, CA, ²Loma Linda University, REDLANDS, CA
Background/Purpose: Gout is the most common inflammatory arthritis in adults that results in high disease burden and health care utilization. The objective of the study…
Abstract Number: 1812 • ACR Convergence 2022
Impact of Misclassification on the US Prevalence of Gout: Bayesian Sensitivity Analysis of the National Health & Nutrition Examination Survey (NHANES)
Lingxiao Chen¹, Yue Zhang² and Kazuki Yoshida³, ¹Kolling Institute, Sydney, Australia, ²University of Utah, Salt Lake City, UT, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Gout is considered the most common inflammatory arthritis in the US with an estimated prevalence of 3.9% based on the National Health and Nutrition…
Abstract Number: 1579 • ACR Convergence 2022
The TICOG Study: Tight Control of Gout – A Randomized, Controlled Trial of Targeted versus Conventional Treatment for Gout Including Ultrasonography
Sarah Black, Natalie McKee, Jonathan McKnight, Annmarie McShane, Adrian Pendleton, Taggart Alister and Gary Wright, Musgrave Park Hospital, Belfast Health and Social Care Trust, Belfast, Northern Ireland, United Kingdom
Background/Purpose: Gout is a common inflammatory arthritis triggered by deposition of monosodium urate crystals in joints, bone and soft tissues, with a prevalence of 1-4%…
Abstract Number: 1796 • ACR Convergence 2022
Peripheral Vascular Disease and Sequelae in Individuals with Gout, Diabetes, or Both Among US Veterans
Nicole Leung¹, Michael Toprover¹, Charles Fang², Michael Pillinger³ and Jay Pendse⁴, ¹Division of Rheumatology, New York University Grossman School of Medicine and Rheumatology Section, New York Harbor Health Care System, New York Campus of the U.S. Department of Veterans Affairs, New York, NY, ²Department of Surgery Division of Vascular and Endovascular Surgery, University of Massachusetts Medical School, Worcester, MA, ³NYU Grossman School of Medicine, New York, NY, ⁴Division of Endocrinology, New York University Grossman School of Medicine and Endocrinology Section, New York Harbor Health Care System, New York Campus of the U.S. Department of Veterans Affairs, New York, NY
Background/Purpose: Peripheral vascular disease (PVD) causes substantial morbidity and mortality. Patients with gout are known to have increased coronary artery disease risk but less is…
Abstract Number: 1814 • ACR Convergence 2022
Pegloticase for Uncontrolled Gout in Patients with History of Kidney Transplant: Pharmacokinetics and Immunogenicity in the PROTECT Clinical Trial
Abdul Abdellatif¹, Yan Xin², Jason Chamberlain³, Lin Zhao², Katya Cherny³, Brad Marder⁴, John D Scandling⁵ and kenneth saag⁶, ¹Kidney Hypertension Transplant Clinic Clear Lake Specialties, Webster, TX, ²Horizon Therapeutics, Deerfield, IL, ³Horizon Therapeutics plc, Deerfield, IL, ⁴Horizon Therapeutics, Denver, CO, ⁵Stanford University School of Medicine, Division of Nephrology, Palo Alto, CA, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Immunomodulator co-therapy with pegloticase has been shown to reduce immunogenicity (anti-drug antibody [ADA] development), which markedly improves response rates with pegloticase while reducing risk…
Abstract Number: 1580 • ACR Convergence 2022
Poor Serum Urate Control Is a Driver of Excess Cardiovascular Risk in Patients with Gout
Tate Johnson¹, Lindsay Helget², Harlan Sayles², Punyasha Roul³, James O'Dell², Ted Mikuls⁴ and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³UNMC, Omaha, NE, ⁴Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Gout patients suffer from an increased burden of cardiovascular disease (CVD). It remains unclear whether this risk is related to an excess of CVD…
Abstract Number: 1797 • ACR Convergence 2022
Factors Driving Opioid Use in United States Veterans with Gout
Lindsay Helget¹, Bryant England¹, Punyasha Roul², Harlan Sayles¹, Alison Petro¹, Tuhina Neogi³, James O'Dell¹ and Ted Mikuls⁴, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³Boston University School of Medicine, Boston, MA, ⁴Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with gout often seek care for painful flares and nearly one-third are prescribed opioids during acute ambulatory visits. Unfortunately, opioids do not address…
Abstract Number: 1815 • ACR Convergence 2022
Consistent Colchicine Use Is Associated with Decreased Major Adverse Cardiovascular Events in Patients with Gout and Established Cardiovascular Disease
Gary Ho¹, Michael Toprover², Daria Crittenden³, binita Shah⁴ and Michael Pillinger⁵, ¹New York University Grossman School of Medicine, VA New York Harbor Health Care System, Brooklyn, NY, ²Division of Rheumatology, New York University Grossman School of Medicine and Rheumatology Section, New York Harbor Health Care System, New York Campus of the U.S. Department of Veterans Affairs, New York, NY, ³CymaBay Therapeutics, New York University Grossman School of Medicine, Newark, CA, ⁴New York University Grossman School of Medicine, VA New York Harbor Health Care System, New York, NY, ⁵NYU Grossman School of Medicine, New York, NY
Background/Purpose: Patients with gout are more likely than those without to have traditional risk factors for cardiovascular (CV) disease. Furthermore, the chronic, low-level inflammation experienced…
Abstract Number: 1581 • ACR Convergence 2022
Presence of Sonographic Crystal Deposits and Power-Doppler Signal in Patients with Gout Fulfilling Remission Criteria: A Multicenter Study
Nalia Domínguez-Lirón¹, Eugenio De Miguel², Agustín Martínez-Sanchis³, Diana Peiteado², Blanca Garcia-Magallon⁴, Esther Vicente-Rabaneda⁵, Enrique Calvo⁶, Basilio Rodríguez⁷, Alejandro Prada⁸, Boris Anthony Blanco Cáceres⁹, José Antonio Bernal¹⁰, Francisca Sivera¹¹, Santos Castañeda⁵, Sonia Mínguez⁷, Laura Barrio⁸, Mónica Vázquez-Díaz⁹, José Miguel Senabre¹², Cristina Bohorquez¹³ and Mariano Andrès³, ¹Miguel Hernández University, Alicante, Spain, ²Hospital Universitario La Paz, Madrid, Spain, ³Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ⁴Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ⁵Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁶Hospital Universitario Infanta Leonor, Madrid, Spain, ⁷Althaia Xarxa Assistencial Universitaria De Manresa, Manresa, Spain, ⁸Hospital Universitario de Torrejon, Madrid, Spain, ⁹Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹⁰Hospital Marina Baixa (Villajoyosa), Alicante, Spain, ¹¹Hospital Universitario de Elda, San Vicente del Raspeig, Spain, ¹²Hospital Marina Baixa, Villajoyosa, Spain, ¹³University Hospital Príncipe de Asturias, Immune System Diseases-Rheumatology Service, Alcalá de Henares, Madrid, Spain
Background/Purpose: The applicability of the preliminary remission criteria for gout [PMID 26414176] in clinical practice is unknown. This study evaluates the sonographic prevalence of monosodium…
Abstract Number: 1798 • ACR Convergence 2022
Health-Related Quality of Life Improvements Resulting from a Treat-to-Target Strategy in the Management of Gout: Post- Hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial
Lindsay Helget¹, James O'Dell¹, Jeff Newcomb¹, Maria Androsenko², Mary Brophy², Anne Davis-Karim³, Bryant England¹, Ryan Ferguson², Michael Pillinger⁴, Tuhina Neogi⁵, Paul Palevsky⁶, Hongsheng Wu² and Ted Mikuls⁷, ¹University of Nebraska Medical Center, Omaha, NE, ²VA Boston Cooperative Studies Program Coordinating Center, Boston, MA, ³VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, ⁴NYU Grossman School of Medicine, New York, NY, ⁵Boston University School of Medicine, Boston, MA, ⁶University of Pittsburgh School of Medicine, Pittsburgh, Pittsburgh, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The ACR recommends a treat-to-target strategy in gout management, centered on the titration of urate lowering therapy (ULT) to a goal serum urate (SU)…
Abstract Number: 1816 • ACR Convergence 2022
Assessing Urate Deposition and Inflammation in the Vasculature of Gout Patients Using Dual Energy Computed Tomography and Positron Emission Tomography Pre and Post Pegloticase- a Pilot Study
Ira Khanna, Venkatesh Mani, Renata Pyzik, Audrey Kaufman, Wei Wei Chi, Emilia Bagiella, Philip Robson and Yousaf Ali, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Gout is the most common inflammatory arthritis, caused by hyperuricemia and subsequent deposition of aggregated monosodium urate (MSU) crystals in both articular and extra-articular…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].